Kriti Nutrients (KRITINUT)

Score breakdown: P/E: 3/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1

Key Financials

Strengths

• Near-zero leverage (D/E 0.03) with strong returns: ROE 16.4%, ROCE 24.46%.
• Promoter holding of 66.68% aligns management with minority shareholders.
• Valuation seems reasonable: P/E 10.8, PEG 0.52, market cap ₹352 Cr.
• Piotroski F-Score 7/9 indicates healthy earnings quality.
• Sales growth of 29.72% shows business expansion momentum.

Concerns

• Profit growth of 11.64% is well below sales growth of 29.72%, suggesting margin compression; latest quarter net margin is only about 4%.
• Edible oil is a commodity business with limited pricing power and likely input-price volatility.
• Low dividend yield of 0.43% gives little compensation while waiting.
• Stock is near the upper end of its 52-week range (₹51.36–₹108.50), so part of the cyclical upcycle may already be priced in.

AI Analysis

At ₹94.35, the market values Kriti Nutrients at just ₹352 Cr. A P/E of 10.8 and a P/B of 2.42 against a book value of ₹38.94 are not demanding. The business earns an ROE of 16.4% and an ROCE of 24.46%, and it carries almost no debt—D/E of 0.03. The Piotroski score of 7/9 and promoter holding of 66.68% also give me comfort about financial health and alignment. But I cannot forget this is an edible-oil company. That is an industry of thin margins and commodity price swings. In the latest quarter, it did ₹224 Cr of sales and kept only ₹9 Cr as profit—a net margin of roughly 4%. Sales grew 29.72%, yet profit grew only 11.64%. That gap tells me the growth is being clipped at the margin level. A low P/E in a cyclically favourable phase can be deceptive. The stock has already moved from a 52-week low of ₹51.36 to ₹108.50, and is currently near ₹94.35, so I am not buying at a distressed price. Still, the balance sheet is strong, and at 10.8 times earnings with a PEG of 0.52, the price is not pricing in much growth. If the company can sustain a 16% ROE and hold or expand margins, this could be an attractive value proposition. The 0.43% dividend yield, though, is small, so I would want any retained capital to earn the same 16%—otherwise cash should be returned. For me, Kriti Nutrients is a well-run cyclical, not a dominant consumer monopoly. I would wait for evidence that margin compression is reversing. The numbers are good; the business nature is the risk.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer